Related Experiment Video

Updated: Jul 10, 2025

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

13.8K

Long non-coding RNAs and tyrosine kinase-mediated drug resistance in pancreatic cancer

Dangran Li1, Shiting Weng2, Kai Zeng3

  • 1Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, China; The State Key Laboratory of Pharmaceutical Biotechnology, College of Life Sciences, Nanjing University, Nanjing 210029, China.

Gene
|November 19, 2023
PubMed

Insights

Pancreatic cancer drug resistance is linked to tyrosine kinases (TKs) and long non-coding RNAs (lncRNAs). Targeting these molecules offers potential for new pancreatic cancer treatments and biomarkers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Pancreatic cancer (PC) exhibits high malignancy and poor survival rates, largely due to chemoresistance.
  • Dysfunctional tyrosine kinases (TKs) and long non-coding RNAs (lncRNAs) are implicated in PC drug resistance and prognosis.

Purpose of the Study:

  • To summarize mechanisms of TKs and lncRNAs in mediating PC drug resistance and malignant phenotypes.
  • To explore the roles and regulatory mechanisms of lncRNAs in PC drug resistance.
  • To highlight the clinical significance and therapeutic potential of TKs and lncRNAs in PC.

Main Methods:

  • Literature review and synthesis of existing research on TKs and lncRNAs in pancreatic cancer.
  • Analysis of molecular mechanisms involving lncRNA-protein and lncRNA-microRNA interactions.
  • Examination of lncRNAs as upstream regulators of TKs.

Main Results:

  • TKs and lncRNAs significantly influence pancreatic cancer drug resistance and overall prognosis.
  • lncRNAs can act as oncogenes or tumor suppressors, employing diverse mechanisms to affect drug resistance.
  • lncRNAs regulate TKs, contributing to chemoresistance in pancreatic cancer.

Conclusions:

  • Specific TKs (AXL, EGFR, IGF1R, MET) and lncRNAs (LINC00460, PVT1, HIF1A-AS1) have clinical significance in pancreatic cancer.
  • TKs and lncRNAs represent promising diagnostic/prognostic biomarkers and potential therapeutic targets for overcoming pancreatic cancer drug resistance.
Keywords:
ChemoresistanceLncRNAMicroRNAPancreatic ductal adenocarcinomaTargeted therapyTyrosine kinase

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.5K
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.0K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K